Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24

Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.

B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.

RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

Berkshire Hathaway Earnings Preview: Six Months After Warren Buffett Stepped Down, Will CEO Greg Abel Boost Buybacks?

Six months after Warren Buffett stepped down, all eyes are on whether CEO Greg Abel accelerates Berkshire Hathaway's buybacks.

Tutor Perini’s Subsidiary Fisk Electric Awarded $24M Electrical Services Contract For Confidential Data Center Customer In Houston, Texas

Tutor Perini Corporation (NYSE:TPC) (the "Company"), a leading civil, building and specialty construction company, announced today that its subsidiary, Fisk Electric Company ("Fisk"), has been awarded an